晚期肝细胞癌患者的TATI综合治疗模式  

TATI comprehensive treatment mode for patients with advanced hepatocellular carcinoma

作　　者：王山 郝建斌 赵杰 郝延璋[1] Wang Shan;Hao Jianbin;Zhao Jie;Hao Yanzhang(Department of Oncology,Binzhou Medical University Hospital,Binzhou 256603,China)

机构地区：[1]滨州医学院附属医院肿瘤科,滨州256603

出　　处：《国际医药卫生导报》2024年第23期3933-3936,共4页International Medicine and Health Guidance News

基　　金：山东省医学会(YXH2022ZX02124)。

摘　　要：肝细胞癌(HCC)是常见的恶性肿瘤之一。目前,HCC的主要治疗方法包括肝移植、手术切除、各种经皮局部治疗[如经导管动脉化疗栓塞术(TACE)和消融等],以及全身治疗[如酪氨酸激酶抑制剂(TKIs)和免疫检查点抑制剂(ICIs)等]。TATI综合治疗模式是将TACE、消融、TKIs和ICIs顺序应用于晚期HCC患者的一种新型疗法,该文通过整理分析近年晚期HCC的最新治疗进展,探索TATI综合治疗模式的可行性及安全性,以期为临床医生提供参考。Hepatocellular carcinoma(HCC)is one of the common malignant tumors.Currently,the main treatment methods for HCC include liver transplantation,surgical resection,various percutaneous modalities,such as transarterial chemoembolization(TACE)and ablation,and systemic treatments,such as tyrosine kinase inhibitors(TKIs)and immune-checkpoint inhibitors(ICIs).The TATI comprehensive treatment mode is a new therapy that sequentially applies TACE,ablation,TKIs,and ICIs to patients with advanced HCC.Reviewing and analyzing the latest treatment advances for patients with advanced HCC in recent years,this article explores the feasibility and safety of the TATI comprehensive treatment mode,so as to provide references for clinical physicians.

关 键 词：肝细胞癌 免疫检查点抑制剂 酪氨酸激酶抑制剂 消融 经导管动脉化疗栓塞术 综述 

分 类 号：R735.7[医药卫生—肿瘤]